(Q45901122)

English

A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians.

scientific article published on 12 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

A meta-regression analysis of the available data on adherence to adjuvant hormonal therapy in breast cancer: summarizing the data for clinicians. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

meta-regression

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

author name string

Laetitia Huiart

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

Cyril Ferdynus

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

language of work or name

0 references

publication date

12 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

138

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

325-328

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Advanced methods in meta-analysis: multivariate approach and meta-regression.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Meta-analysis of longitudinal studies.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adjuvant hormonal therapy use among insured, low-income women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Use of tamoxifen and aromatase inhibitors in a large population-based cohort of women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adherence beliefs among breast cancer patients taking tamoxifen

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Adherence to tamoxifen over the five-year course

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: a population-based analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Conducting Meta-Analyses in R with the metafor Package

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2422-4

21 January 2018

Identifiers

10.1007/S10549-013-2422-4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/23400580

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45901122&oldid=2207437153"